After the approval of immune checkpoint inhibitors, overall survival among US patients with advanced-stage cancer improved, but disparities between uninsured and privately insured widened.

Panelists discuss treatment considerations for metastatic melanoma with high tumor burden, highlighting the preference for immune checkpoint combinations like nivolumab with relatlimab for durable ...